



PROGRAM ANNOUNCEMENT

MOVEMBER GLOBAL CANCER REAL WORLD EVIDENCE NETWORK

EXPRESSIONS OF INTEREST: GLOBAL COLLABORATIVE PROGRAM TO REDUCE THE NUMBER OF MEN PROGRESSING TO ADVANCED PROSTATE CANCER

LAUNCH DATE: 25 NOVEMBER 2021

CLOSING DATE: 5 JANUARY 2022

Movember, in collaboration with Prostate Cancer UK, is pleased to invite expressions of interest (EOI) from suitably qualified and experienced research teams to participate in a new, global, collaboratively designed program. The goal of the program is to accelerate efforts aimed at reducing the number of men who progress to advanced prostate cancer, by bringing together a network of disciplines within the prostate cancer research community.

This program is a Movember investment of up to AU \$7 million and is the first program launched as part of Movember's Global Cancer Real World Evidence Network. The Network, in its final form, will comprise over 600 participating hospitals and research institutions across 19 countries, with the aims to accelerate improvements in the survival and quality of life of men living with prostate and testicular cancer. The Network will provide an opportunity for this global collaborative program to fast-track the delivery of lifesaving tests and treatments to improve the physical and mental health of men living with the disease.

RATIONALE

Prostate cancer remains a significant contributor to the global cancer burden, which leads to an estimated 375,000 deaths worldwide in 2020^{1,2}. As new, life-prolonging systemic treatments continue to be developed for metastatic, castrate-resistant prostate cancer, the heterogeneity of this disease stage has been proposed to be, at least in part, responsible for treatments having no or limited efficacy.

Introduction of treatments earlier in the course of the disease, before the cancer reaches a heterogeneous, treatment-resistant state, may provide an opportunity for complete eradication of localised or micro-metastatic, hormone-sensitive disease. Certainly, this approach has led to substantial changes to the treatment landscape of high-risk, locally advanced prostate cancer and metastatic, hormone-sensitive prostate cancer (mHSPC) over the past decade, with continuing introduction of new systemic agents accompanied by improved outcomes.

While the rationale that earlier intervention represents one of the most viable ways to decrease prostate cancer death prevails, clinicians (and the men they care for) remain challenged with the selection and sequencing of available treatments, some of which have seemingly comparable efficacy. Optimal treatment selection is further complicated by other considerations, including the duration and timing of therapy, the impact of possible side effects and disparities in patient access to new treatments, to identify which men will benefit most without compromising on the quality of life.

There is therefore a strong rationale to invest in the development of a comprehensive treatment selection approach with robust evidence base that can inform the most appropriate treatment at the earlier opportunity for a man's disease to half disease progression.

SUCCESS OF THE PROGRAM

The ultimate success of this program, in line with Movember's global biomedical research strategy, would be to reduce the number of men with high-risk, locally advanced prostate cancer and mHSPC who ultimately progress to advanced disease, with the aim to deliver improved outcomes within the next five years.

We believe this goal can be achieved through robust improvements in current hormonal and/or systemic therapies, combined with population-based implementation and precision treatment selection in a global, collaborative effort to accelerate progress.



MOVEMBER FUNDING PRIORITY & PROGRAM OBJECTIVE

Movember is looking to fund a globally collaborative, co-designed project (OR group of global projects sharing key research objectives) to investigate the ways in which **existing and/or emerging hormonal or systemic therapies for high-risk, locally advanced prostate cancer or mHSPC can be selected and/or sequenced, to ensure the right treatment for the right patient at the right time.**

Interested and suitably qualified investigators will form a globally integrated team which, through a consensus-based collaboration, will develop a unified approach to address the key questions surrounding treatment selection and sequencing for men with prostate cancer who are at high risk of progressing to advanced disease.

Expressions of interest must be directly related to high-risk, locally advanced prostate cancer or mHSPC (including *de novo* metastatic disease) to:

- Support the development of a robust evidence base to demonstrate the clinical utility of a comprehensive treatment selection process through prospective studies,
or
- Support the integration of existing databases on a global scale for more efficient progress to better understand the unique biology of these cancers and to define the role of new and current available therapies,
and
- Incorporate the collection and utilisation of real-world data in driving practice change.

This global collaboration aims to:

- Establish a multi-disciplinary collaboration that brings together different expertise within the research communities, including imaging, radiation oncology, medical oncology and urology
- Support the structured, standardised collection of real-world data that is considered critical in supporting equity of care
- Leverage the Movember Global Cancer Real World Evidence Network as well as existing Movember programs and networks in building the evidence base to support the unmet need and/or value of treatment selection process in clinical practices
- Leverage research implementation capabilities and co-funding and/or partnership opportunities.

It is not expected that co-ordinated networks (either formal or informal) will collaborate in responding to this EOI, however both individual submissions and submissions from existing networks will be accepted for consideration.

PROGRAM PARTICIPATION REQUIREMENTS

This program is intentionally ambitious and will strive to contribute to Movember's goal to change the face of men's health. It is the expectation that participants in the program will openly and collaboratively share data and knowledge to significantly improve the efficiency of research in this area.

Pending on the EOI submissions, the final project may take the shape of a single, unified and cohesive body of work OR multiple projects of smaller scale with contributors from all over the world.

The majority of funding to support this initiative comes from Movember fundraising campaigns in Australia, Ireland, Canada, United Kingdom and the USA and we would anticipate that a significant amount of program funding would be applied to investigators in these countries. Applicants from outside these countries are also welcome and encouraged to apply.

PROCESS

1. This EOI is not a call for detailed project proposals. The purpose of this EOI is to garner interest and assess research ideas, available resources, and research team capabilities for the development of a single collaborative research project (OR groups of projects) on a global scale. Movember is seeking to identify potential areas of collaboration through the initial EOI submissions.
2. Review and assessment of EOIs by an independent Program Advisory Committee (PAC), with Movember as the funder to facilitate and coordinate this program / project establishment process.

3. Investigators selected by the PAC will be invited to join a working group(s) to collaborate on the development of a full program / project proposal.
4. Utilising a consensus-based model, working group(s) will come together to create a project that addresses the objectives of the program, whilst simultaneously utilising the global capability and capacity of the investigators selected to participate in the project. One investigator will be nominated as the lead investigator to coordinate the submission of a complete project proposal from the working group(s) with the responsibility continues until project completion. Pending COVID-related travel restrictions, there may be an opportunity to host the face-to-face working group workshops in February 2022.
5. Shortly after the submission of project proposal, the working group(s) will have the opportunity to present the project plan and address any questions from the PAC in a virtual meeting.
6. The working group(s) will be required to submit a final project proposal, including responses to PAC feedbacks where necessary, project deliverables / milestones, and detailed project budget, for final review and assessment on funding decision.
7. Successful project proposals are expected to be announced by June 2022.
8. A Program Steering Committee (PSC) will be appointed prior to commencement of the program(s) – whose role is to provide ongoing governance and scientific feedback throughout the life of the program.

EXPRESSIONS OF INTEREST

We are calling for suitably qualified and experienced investigators to express their interest in participating in this program. To submit your EOI, please complete the form via the link below **by 5 January 2022**:

https://movember.qualtrics.com/jfe/form/SV_cUDqmHnvEsMaLrw

Movember will acknowledge receipt of EOI via email provided within two business days.

A list of FAQs will be posted on <https://movember.com/about/funding> with regular (weekly) updates.

Received EOIs will be evaluated for:

- Capability of research team – including track record of the team in establishing collaboration and/or partnerships
- Availability of resources – including existing pathway to ensure access to necessary data and/or resources required for the proposed research

TIMELINE

Milestones	Dates
EOI announcement	25 November 2021
EOI submission deadline	5 January 2022
EOI review by the Program Advisory Committee	10 January 2022 – 4 February 2022
Invitation to submit full project proposal from nominated working group/s	Week of 7 February 2022
Potential Project Steering Committee workshop(s)	Week of 14 February 2022 (at ASCO-GU / 17-19 February 2022, San Francisco, US)
Project proposal submission deadline	1 April 2022
Presentation of study proposal to Program Advisory Committee	(TBC) Week of 18 & 25 April 2022
Final project proposal submission (rebuttal)	(TBC) Week of 9 May 2022
Final project proposal review & assessment	(TBC) Week of 30 May 2022
Program outcome announcement	(TBC) Week of 20 June 2022

CONTACT

All enquires relating to this funding opportunity should be directed to Sarah Hsiao, Director (Biomedical Research & Impact) at biomed@movember.com.



ABOUT MOVEMBER

Movember is the leading charity changing the face of men's health on a global scale, focusing on prostate cancer, testicular cancer and mental health and suicide prevention. We invest strategically in priority areas that will help men to live happier, healthier and longer lives. With a global presence across 21 countries, Movember's is uniquely placed to break down barriers and build collaborative teams on a global scale.

REFERENCES

1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71, 209–249 (2021).
2. Fedewa, S. A., Ma, J. & Jemal, A. Response to Lehrer and Rheinstein. *J. Natl. Cancer Inst.* 112, 1069–1070 (2020).